MedPath

Differential Diagnostic of Immune ThrombocytoPenia (ITP) and Myelodysplastic Syndrome (MDS)

Completed
Conditions
Myelodysplastic Syndromes
Immune Thrombocytopenia
Registration Number
NCT03469661
Lead Sponsor
Fundacion CRIS de Investigación para Vencer el Cáncer
Brief Summary

Current diagnostic criteria for Immune ThrombocytoPenia (ITP) are mainly based on the presence of low numbers of platelets, excluding other multiple causes of thrombocytopenia, including immunodeficiencies, constitutional or acquired thrombocytopenia, hypersplenism and clonal hematological disorders such as MDS, disorders lymphoproliferative and acute myeloid leukemia (AML), among others. The analysis complementary tests for the diagnosis of ITP include studies basic systematic hematology, together with autoimmune assays and microbiological tests, while the evaluation of bone marrow is limited to elderly patients and/or patients resistant to treatment. Previous research has described the development of Myelodysplastic Syndrome (MDS) in patients with a previous diagnosis of ITP, and even the presence of MDS associated with genetic background. Therefore, it is conceivable fact that a percentage of cases with clinical signs of ITP in the moment of appearance may actually correspond to the first stages of MDS development in which bone marrow cells are not systematically evaluated in the initial presentation.

The anomalous immunophenotypic patterns between multiple compartments of bone marrow cells and peripherally blood (PB) platelets have been characterized through flow cytometry. The flow cytometry currently represents an important complementary tool for diagnosis of MDS that has shown great effectiveness and applicability in the differential diagnosis of non-clonal cytopenias against early MDS and for the detection of stages prior to MDS. Besides, the flow cytometry has made it possible to detect the presence of coexisting features related to MDS in patients with other malignancies hematologic conditions such as multiple myeloma, AML, and lymphocytic leukemia chronic. Therefore, the immunophenotypic analysis of the cells of the bone marrow of patients with ITP at the time of appearance would help to identify the cases that underlie clonal hematopoiesis MDS type. In the present study it is planned a broad characterization immunophenotyping of multiple compartments of bone marrow cells and PB platelets from patients with recently diagnosed ITP and investigate their morphological antecedents, in order to identify those patients who show compatible clonal hematopoietic patterns with MDS evident (or at risk of development), as candidates to receive most appropriate therapeutic methods.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
63
Inclusion Criteria
  • Patients aged ≥ 18 years old at diagnosis
  • Informed consent in writing
  • Newly diagnosed primary ITP patients, or
  • Newly diagnosed MDS patients
Exclusion Criteria
  • Patients who participated in a interventional thrombopoietin receptor agonists (TPO-RA) clinical trial since TPO-RA treatment initiation
  • Patients with secondary immune thrombopenia

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Morphological profileBaseline

Peripheral blood platelets profiles

Immunological profileBaseline

Peripheral blood platelets profiles

Secondary Outcome Measures
NameTimeMethod
Immunophenotypic abnormalitiesBaseline

Evaluation of abnormal immunophenotypic profiles

Morphological abnormalitiesBaseline

Evaluation of abnormal morphological profiles.

Trial Locations

Locations (6)

Hospital Virgen de la Victoria

🇪🇸

Málaga, Spain

Complejo Hospitalario de A Coruña

🇪🇸

A Coruña, Spain

Hospital Regional de Málaga

🇪🇸

Málaga, Spain

Hospital Ramon y Cajal

🇪🇸

Madrid, Spain

Hospital de Burgos

🇪🇸

Burgos, Spain

Hospital Universitario Insular de Gran Canaria

🇪🇸

Las Palmas De Gran Canaria, Spain

© Copyright 2025. All Rights Reserved by MedPath